Exjade (deferasirox)

Manufacturer:
Novartis
Route of Administration: 
Oral
Site of Care:
Outpatient
Website: 
    Enrollment Forms:
    Synergen Prescription Form

    Approved Indication:

    • treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older
    • treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia syndromes and with a liver iron (Fe) concentration of at least 5mg Fe per gram of dry weight and a serum ferritin greater than 300mcg/L

    Conditions:

    • Sickle Celll Disease
    • Anemia
    • Non-Transfusion-Dependent Thalassemia

    Therapeutic Area:

    • Oncology